Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Modular Medical, Inc. (MODD)

Modular Medical director Duane DeSisto resigns from board after annual meeting

Neutral Impact 2 of 5 leadership Written later

Modular Medical director Duane DeSisto resigned from the board effective immediately on October 26, 2026, and the company said the resignation was not due to a disagreement over its operations, policies or practices. At the October 23, 2026 annual meeting, shareholders re-elected the board slate, approved a 2,500,000-share increase to the equity incentive plan, and ratified Farber Hass Hurley LLP as auditor for the fiscal year ending March 31, 2027.

Key points

  • Duane DeSisto resigned from the board on October 26, 2026, effective immediately, with no disagreement cited.
  • Approximately 65% of outstanding common shares were represented at the October 23, 2026 annual meeting.
  • Shareholders approved the equity incentive plan amendment, with 2,294,200 votes for and 811,943 against.
  • Shareholders ratified Farber Hass Hurley LLP with 6,171,976 votes for and 15,512 against.

The filing

CompanyModular Medical, Inc. (MODD)
Form8-K, current report
Filed with the SECOct 28, 2026, 4:10 PM ET
Accession number0001213900-26-113310

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.